Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin associated with ultraviolet exposure. Although uncommon, its incidence is increasing and has in fact tripled in the past 15 years (Hodgson, 2005) . The rise in incidence is due in part to improved diagnosis through the dence of cutaneous T-cell lymphoma, a well-known and frequently studied cancer, whose incidence has been stable since the early 1980s (Weinstock and Gardstein, 1999) . MCC is also one of the most lethal skin cancers, with a 33% mortality (Hodgson, 2005) -it now kills more patients than cutaneous T-cell lymphoma and a number similar to that for chronic myelogenous leukemia (Figure 1 ) (American Cancer Society, 2006; Weinstock and Gardstein, 1999) . Despite the mortality and increasing incidence, virtually nothing is known about the molecular basis of MCC. Several studies of oncogenic pathways have been carried out in MCC but have not elucidated a significant role for these pathways in this cancer (Table 1) . Van Gele et al. (2000) revealed a lack of p53 mutations in 12 of 15 cases of MCC. Three of the five p53 mutations found in three tumors were of the signature UV type, consistent with MCC's known association with UV exposure. The lack of p53 mutations in 80% of MCCs, however, suggests that p53 is not typically involved in this cancer. The same group (Van Gele et al., 2001 ) also looked at the role of the tumor suppressor PTEN. Although loss of heterozygosity (loss of one allele) was seen in 9 of 21 cases (mostly involving loss of the entire arm of chromosome 10), only a single mutation was seen in the remaining allele of one MCC case. Thus, inactivation of PTEN (by loss of one allele and disruption of the second) does not play a frequent role in MCC oncogenesis. It is possible, however, that loss of a second PTEN allele would be via an epigenetic silencing mechanism such as methylation, which has not been examined.
The Wnt pathway and its role in MCC have also been evaluated by looking for nuclear accumulation of β-catenin and for mutations in β-catenin and three other related genes. In a series of 12 MCC cases, Liu et al. (2007) found elevated β-catenin accumulation in only one tumor and no mutations in any tumors and concluded that the Wnt pathway is not implicated in MCC. Several studies have reported on c-Kit expression in MCC tumor samples. Most recently, Swick et al. (2007) determined that although eight of nine MCC tumors were positive for c-Kit by immunohistochemical staining, no activating mutations were present in the four exons commonly found to have mutations in this gene.
MAP kinase signaling, a common feature of many epithelial cancers, is the most studied oncogenic pathway in MCC (Figure 2) . Popp et al. (2002) looked for activating mutations in exons 1 and 2 of the H-, K-, and N-ras genes in six MCC cell lines but found none. (Schubbert et al., 2007) . The sole potentially positive finding in MCC is that of bcl-2. Its expression was seen in 15 of 20 MCC tumors in two studies (Kennedy et al., 1996; Plettenberg et al., 1996) . A separate study determined that decreasing bcl-2 expression in vivo by systemic antisense oligonucleotide (oblimersen/Genasense) administration in a SCID mouse/human tumor xenograft model resulted in tumor shrinkage (Schlagbauer-Wadl et al., 2000) . The expression of this anti-apoptosis protein is a common finding in many cancers and suggests one of its mechanisms to avoid cell death; however, it does not illuminate the promitotic pathways that drive MCC.
In this issue of the Journal of Investigative Dermatology, Houben et al. (2007) expand on their findings noted above, that the MAP kinase pathway is silent in 42 of 44 MCC tumors. Using an MCC cell line (UISO) that, like primary tumors, shows no evidence of MAP kinase activity, they tested whether activating this pathway could result in MCC cell death. Indeed, inducible expression of c-Raf-1 kinase in the UISO MCC cell line resulted in morphologic changes and apoptosis. Rounding up and detachment of cells, development of long cytoplasmic extensions, and loss of actin stress fibers were seen beginning at 10 hours after activation of the pathway. Further, they demonstrated that active Raf kinase induced apoptosis in UISO cells in a time-and dosedependent manner. This appears to be via a classic apoptotic pathway because it was blocked by a caspase inhibitor (Z-VAD-FMK). The fact that a MEK kinase inbibitor (U0126) also blocked Raf's ability to induce apoptosis suggests that the Raf effect is indeed mediated via the predicted MAP kinase pathway (Houben et al., 2007) .
A limitation of the study is that it was performed in a single MCC cell line. Few reagents for MCC are available to study, and of the available cell lines, only one (UISO) had preservation of the MCC in vivo characteristic of silencing of the MAP kinase pathway. The lack of cell death observed in the study from Raf overexpression in other cell lines positive for MAP kinase activity (three melanoma lines and two other MCC lines) argues for some level of specificity for the cell-death effect to cells that are silent for MAP kinase activity.
The striking lack of knowledge of what drives MCC oncogenesis is an important impediment because no effective targeted therapies exist. Molecular therapies used in other malignancies are now being extended to clinical trials in MCC. Phase II trials of imatinib (Gleevec) and oblimersen (Genasense) are currently under way in MCC. The tyrosine kinase inhibitor imatinib, initially designed to target the Bcr-Abl translocation in chronic myelogenous leukemia, is being explored because of the c-Kit positivity of MCC. Recent data from Swick et al. (2007) suggest that its effectiveness may be limited, however, given that no c-Kit-activating mutations were seen in their series. The bcl-2 inhibitor oblimersen is also in a phase II trial for MCC, but no results of its efficacy in humans with MCC have been published.
The present study by Houben et al. (2007) provides data for the possible use of MAP kinase pathway-activating agents in MCC. Use of the Raf-1 activator ZM336372 did indeed induce ERK phosphylation in UISO MCC cells that are normally silent for MAP kinase signaling. A separate study using carcinoid tumor cells (another neuroendocrine carcinoma) demonstrated that in vitro treatment with ZM336372 inhibited cellular proliferation (Van Gompel et al., 2005) . The data suggest that pharmacologic activation of this normally silent pathway is a potential target for treatment of certain neuroendocrine tumors.
Even Photocarcinogenesis is most commonly thought to be the result of a chain of events that involve formation of DNA damage and subsequent mutation formation following exposure to ultraviolet light (UV) (Figure 1) (Rünger, 2003) . Several cellular defense mechanisms reduce the likelihood that one occurrence in this cascade leads to the next (Figure 1 ). Many of these protective responses can be induced by UV, thereby providing additional protection against subsequent exposures. All of these responses are mediated by a tightly controlled network of signaling pathways, many of which involve the tumor suppressor p53. UV-induced mutations of p53 with subsequent disruption of cellular damage responses are a hallmark of most sun-induced cutaneous squamous-cell carcinomas (Brash et al., 1996) . This further underlines the importance of these damage responses for the prevention of photocarcinogenesis.
The melanin microparasol that covers the nucleus of basal keratinocytes reduces formation of DNA damage with exposure of the skin to UV. Once DNA damage is formed, most of it is repaired and does not give rise to mutations. This is exemplified by the genodermatosis xeroderma pigmentosum, in which the relative inability to repair UV-induced DNA damage results in UV hypermutability in cells and an increased frequency of skin cancers in UV-exposed areas of affected patients. Another mechanism that inhibits mutation formation at sites of DNA damage is a G1/S cell-cycle arrest that prevents cells from replicating damaged DNA, a situation particularly prone to the introduction of mutations (Decraene et al., 2001) . DNA polymerase η, which is mutated in xeroderma pigmentosum variant, is a translesion DNA polymerase spe-
